Q-omics provides the consensus-scored ANAPC1P5 profile across patient tissues and cancer cell-line models. ANAPC1P5 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ANAPC1P5 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, ANAPC1P5 RNA expression shows 5,564 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, LUAD, and STAD as cancer lineages where ANAPC1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANAPC1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANAPC1P5 survival associations across molecular data types. ANAPC1P5 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANAPC1P5 RNA expression–survival associations across cancer types. High ANAPC1P5 expression shows unfavorable associations in THCA, UCS, BLCA, DLBC and LUSC, but favorable associations in STAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for ANAPC1P5 RNA expression.
This table summarizes ANAPC1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANAPC1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANAPC1P5 shows higher tumor expression in LUAD, KIRC, ESCA and LIHC. The LUAD box plot shows higher ANAPC1P5 RNA expression in tumor versus normal tissue (log2 FC = +0.210, t-test p = .008).
This table shows molecular features associated with ANAPC1P5 in patient tissues and cancer cell lines. In patient samples, ANAPC1P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
